REPRODUKTIV YOSHDAGI AYOLLARDA NOSPETSIFIK SERVITSITNI KOMPLEKS DAVOLASHDAN KEYINGI QAYTALANISH XAVFINI BAHOLASH VA PROGNOSTIK MEZONLAR
Kalit so‘zlar:
nospetsifik servitsit, reproduktiv yosh, qaytalanish, retsidiv xavfi, prognostik mezonlarAbstrak
Mazkur maqolada reproduktiv yoshdagi ayollarda nospetsifik servitsitni kompleks davolashdan keyingi qaytalanish xavfini baholash hamda kasallik retsidivini prognozlash imkonini beruvchi klinik va laborator mezonlarni aniqlash masalalari yoritilgan. Nospetsifik servitsitda davolashning dastlabki klinik samaradorligi bilan bir qatorda, uzoq muddatli natijalarni barqarorlashtirish va qaytalanish ehtimolini kamaytirish muhim klinik vazifa hisoblanadi. Tadqiqotda davolashdan keyingi klinik simptomlar dinamikasi, bachadon bo‘yni holati, sitologik ko‘rsatkichlar, servikal kanalning tozalik darajasi hamda yallig‘lanish va oksidativ stress bilan bog‘liq laborator ko‘rsatkichlarning prognostik ahamiyatini kompleks baholash yondashuvi ko‘rib chiqildi. Standart terapiya, trombotsitlarga boy autoplazma (PRP) qo‘llanilgan davolash hamda standart terapiya va PRP kombinatsiyasidan keyingi natijalarni kuzatish asosida qaytalanish xavfini belgilovchi omillarni tizimlashtirish nazarda tutildi. Kasallikning qaytalanishini faqat klinik belgilar asosida emas, balki klinik, sitologik va laborator ko‘rsatkichlar majmuasi asosida prognozlash davolash taktikasini individuallashtirish va yuqori xavf guruhidagi bemorlarni maqsadli kuzatish uchun istiqbolli yondashuv sifatida asoslanadi. Olingan natijalar nospetsifik servitsitni davolashda qisqa muddatli klinik javobdan uzoq muddatli prognozni boshqarishga yo‘naltirilgan yondashuvni takomillashtirishga xizmat qiladi.
##plugins.themes.default.displayStats.downloads##
Havolalar
1. Workowski K.A., Bachmann L.H., Chan P.A., Johnston C.M., Muzny C.A., Park I., Reno H., Zenilman J.M., Bolan G.A. Sexually transmitted infections treatment guidelines, 2021 // MMWR Recommendations and Reports. – 2021. – Vol. 70, No. 4. – P. 1–187. DOI: 10.15585/mmwr.rr7004a1.
2. Lusk M.J., Konecny P. Cervicitis: a review // Current Opinion in Infectious Diseases. – 2008. – Vol. 21, No. 1. – P. 49–55. DOI: 10.1097/QCO.0b013e3282f3d402.
3. Marrazzo J.M., Martin D.H. Management of women with cervicitis // Clinical Infectious Diseases. – 2007. – Vol. 44, Suppl. 3. – P. S102–S110. DOI: 10.1086/511423.
4. Taylor S.N. Cervicitis of unknown etiology // Current Infectious Disease Reports. – 2014. – Vol. 16. – Article 409. DOI: 10.1007/s11908-014-0409-x.
5. Brunham R.C., Paavonen J., Stevens C.E., Kiviat N., Kuo C.C., Critchlow C.W., Holmes K.K. Mucopurulent cervicitis — the ignored counterpart in women of urethritis in men // New England Journal of Medicine. – 1984. – Vol. 311, No. 1. – P. 1–6. DOI: 10.1056/NEJM198407053110101.
6. Donders G.G.G., Bellen G., Ruban K.S. Abnormal vaginal microbioma is associated with severity of localized provoked vulvodynia. Role of aerobic vaginitis and Candida in the pathogenesis of vulvodynia // European Journal of Clinical Microbiology & Infectious Diseases. – 2018. – Vol. 37. – P. 1679–1685. DOI: 10.1007/s10096-018-3299-2.
7. Bos-Mikich A., de Oliveira R., Frantz N. Platelet-rich plasma therapy and reproductive medicine // Journal of Assisted Reproduction and Genetics. – 2018. – Vol. 35. – P. 753–756. DOI: 10.1007/s10815-018-1159-8.
8. Alves R., Grimalt R. A review of platelet-rich plasma: history, biology, mechanism of action, and classification // Skin Appendage Disorders. – 2018. – Vol. 4, No. 1. – P. 18–24. DOI: 10.1159/000477353.
9. Everts P., Onishi K., Jayaram P., Lana J.F., Mautner K. Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020 // International Journal of Molecular Sciences. – 2020. – Vol. 21, No. 20. – Article 7794. DOI: 10.3390/ijms21207794.
10. Dhurat R., Sukesh M. Principles and methods of preparation of platelet-rich plasma: a review and author’s perspective // Journal of Cutaneous and Aesthetic Surgery. – 2014. – Vol. 7, No. 4. – P. 189–197. DOI: 10.4103/0974-2077.150734
